Castle Biosciences Inc. announced new data from its clinical studies, set to be presented at the 25th Annual Fall Clinical Dermatology Conference taking place October 23-26, 2025. The company will present findings from a prospective, multicenter development and validation study of its pipeline atopic dermatitis $(AD)$ gene expression profile (GEP) test. Results demonstrate that the test can identify patients with a JAK inhibitor (JAKi) responder profile who are more likely to benefit from JAKi treatment compared to those receiving Th2-targeted therapy. The data suggest the test may help guide personalized treatment decisions in moderate-to-severe AD. Additionally, Castle Biosciences will present new analysis from 13,560 patients showing that its DecisionDx®-Melanoma test provides clinically relevant risk stratification across multiple histological subtypes of melanoma. This analysis confirms the clinical value of the test in offering prognostic information to inform risk-aligned management plans for melanoma patients.